This work substantiated that weekly GA-administration for 12 weeks during the early stage of AD prior to amyloid deposition improved cognitive performance and alleviated Aβ pathology in APP/PS1 mice through its effect on the amplification of peripheral Tregs, reduction of microglia activation, and increased the level of anti-inflammatory cytokines. The gene discussed is APP; the disease is amyloidosis.